GLP-1 Medications and Fertility: Current Research

Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 receptor agonists like semaglutide have transformed the landscape of weight loss therapy, with millions of patients achieving meaningful metabolic improvements. As fertility concerns remain top-of-mind for reproductive-age patients, understanding how these medications interact with reproductive health is essential for informed treatment decisions.

How GLP-1 Medications Work and Reproductive Health

GLP-1 receptor agonists function by enhancing insulin sensitivity, slowing gastric emptying, and signaling fullness to the brain—none of which directly target reproductive hormones or egg or sperm production. The GLP-1 receptor exists throughout the body, but reproductive tissues express minimal to negligible amounts, suggesting systemic GLP-1 activation has limited direct impact on fertility at the cellular level. Animal studies and early human trials have not demonstrated that GLP-1 medications impair gonadal function or alter critical reproductive pathways.

Weight loss itself, however, profoundly influences reproductive health. Excess adipose tissue produces estrogen and inflammatory cytokines that can disrupt ovulation, reduce sperm quality, and increase miscarriage risk. By reducing body weight through semaglutide or other GLP-1 compounds, patients often experience restoration of regular menstrual cycles, improved insulin sensitivity, and lower inflammation—all factors associated with better fertility outcomes. This metabolic restoration may represent one of the most significant fertility benefits for patients struggling with obesity-related reproductive dysfunction.

Clinical Evidence on GLP-1 Use and Pregnancy Outcomes

Major clinical trials including SUSTAIN and PIONEER series did not identify concerning patterns of birth defects, miscarriage, or adverse neonatal outcomes in pregnancies exposed to GLP-1 medications. However, most pregnant participants in these trials stopped treatment upon pregnancy confirmation, reflecting current prescribing guidance. The FDA has not classified semaglutide or tirzepatide as absolutely contraindicated in pregnancy, though both manufacturers recommend discontinuation before conception or as soon as pregnancy is confirmed due to limited long-term safety data in utero.

Observational data from pregnant patients with type 2 diabetes who continued GLP-1 therapy has not raised specific red flags, though prospective studies comparing outcomes in women who continued versus discontinued treatment remain limited. The metabolic benefits of improved glycemic control and reduced maternal weight may theoretically support healthier pregnancies in diabetic populations, but current evidence does not yet establish routine use during pregnancy. PlexusDx recommends discussing pregnancy planning and medication continuation with a qualified fertility specialist or obstetrician before conception.

GLP-1 Therapy and Ovulation, Menstrual Regularity, and Egg Quality

Polycystic ovary syndrome (PCOS) affects approximately 8–13% of reproductive-age women and ranks as a leading cause of anovulation and infertility. PCOS is fundamentally an insulin resistance and metabolic disorder, making GLP-1 medications a rational therapeutic choice for improving insulin sensitivity and restoring ovulatory function. Clinical case series and small cohort studies report that patients with PCOS who achieve weight loss via GLP-1 therapy often experience resumption of regular menstrual cycles, improved testosterone ratios, and reduced anti-müllerian hormone (AMH) variability—markers of improved ovarian reserve and egg quality.

The mechanism likely involves a combination of direct metabolic effects (enhanced insulin signaling reducing hyperinsulinemia) and indirect effects (weight loss reducing inflammatory adipokines and excess estrogen production). While large randomized fertility trials specifically examining GLP-1 agents in PCOS remain sparse, existing evidence supports using these medications as adjunctive therapy alongside lifestyle modification and fertility specialist oversight for ovulatory dysfunction tied to metabolic dysfunction.

Fertility Planning and GLP-1 Treatment: Timing and Personalized Strategies

Patients considering pregnancy should initiate a conversation with PlexusDx clinicians and their fertility specialists several months before attempting conception. This allows time to establish metabolic stability, assess whether the patient has reached target weight loss and glucose control, and coordinate medication cessation if needed. For many patients, delaying pregnancy by 3–6 months while continuing GLP-1 therapy results in better metabolic health, reduced inflammation, and improved fertility markers at the moment of conception attempt—ultimately shortening time to pregnancy despite the temporary delay.

PlexusDx's Precision Peptide Genetic Test identifies individual variations in GLP1R, GIPR, FTO, and MC4R genes that predict medication response and metabolic trajectory. Understanding your genetic predisposition to peptide-pathway signaling and weight loss capacity can inform realistic timelines for fertility planning. Patients with genetic profiles suggesting slower metabolic response may benefit from extended GLP-1 therapy before conception, while rapid responders may reach optimal metabolic status faster. This personalized approach ensures treatment aligns with your unique reproductive timeline and health goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Will semaglutide or tirzepatide reduce my chances of getting pregnant?

Current evidence does not show that GLP-1 medications directly impair fertility. In fact, weight loss achieved through these drugs often restores regular ovulation and improves sperm parameters in men. The key is timing: discontinue GLP-1 therapy upon pregnancy confirmation and work with a fertility specialist if conceiving takes longer than expected.

What does the research say about GLP-1 medications and miscarriage risk?

Major clinical trials have not identified increased miscarriage rates in pregnancies with prior GLP-1 exposure. Metabolic improvements from weight loss may actually reduce miscarriage risk by lowering inflammation and improving insulin sensitivity. Discontinue GLP-1 therapy as soon as pregnancy is confirmed and follow your obstetrician's prenatal guidance.

Can I use PlexusDx semaglutide while trying to conceive?

Yes. Semaglutide starting at $149/month from PlexusDx is available to patients actively pursuing pregnancy, provided they plan to discontinue upon positive pregnancy test. Many fertility specialists recommend continuing GLP-1 therapy during the preconception period to optimize metabolic health and ovulatory function, then stopping once pregnancy is achieved.

How does weight loss from GLP-1 therapy improve fertility outcomes?

Excess body weight disrupts reproductive hormones, increases inflammation, and impairs egg and sperm quality. GLP-1-induced weight loss reverses these mechanisms by lowering estrogen production from adipose tissue, restoring insulin sensitivity, and reducing inflammatory markers—all linked to improved ovulation rates and pregnancy success.

How can PlexusDx Precision Peptide Genetic Testing help with fertility planning?

The Precision Peptide Genetic Test ($99 add-on after first month) analyzes your GLP1R, GIPR, FTO, and MC4R variants to predict how quickly you'll respond to GLP-1 therapy and achieve metabolic improvement. This insight helps you and your fertility specialist set realistic timelines for GLP-1 treatment before conception, ensuring optimal reproductive health timing.

Related Reading

• Glp 1 Medications
• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• Can A Dna Test Reveal If I Will Benefit From Glp 1 Medications
• Maximus Glp 1

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.